|
gptkbp:instanceOf
|
substance abuse
dissociative drug
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:CASNumber
|
1239943-76-0
|
|
gptkbp:chemicalClass
|
gptkb:methoxetamine
|
|
gptkbp:developedBy
|
recreational drug
|
|
gptkbp:drugClass
|
NMDA receptor antagonist
norepinephrine reuptake inhibitor
|
|
gptkbp:effect
|
hallucination
dissociation
sedation
euphoria
analgesia
|
|
gptkbp:eliminationHalfLife
|
3-6 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstSynthesized
|
2010
|
|
gptkbp:hasMolecularFormula
|
C15H21NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MXE
|
|
gptkbp:IUPACName
|
gptkb:2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone
|
|
gptkbp:legalStatus
|
illegal in Germany
illegal in Canada
illegal in China
illegal in United Kingdom
illegal in United States
|
|
gptkbp:mainStreet
|
gptkb:roflcoptr
mexxy
mket
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
247.33 g/mol
|
|
gptkbp:notApprovedForMedicalUse
|
true
|
|
gptkbp:relatedTo
|
gptkb:ketamine
gptkb:phencyclidine
|
|
gptkbp:routeOfAdministration
|
oral
insufflation
intramuscular injection
|
|
gptkbp:sideEffect
|
confusion
nausea
vomiting
hypertension
tachycardia
urinary tract symptoms
|
|
gptkbp:toxicity
|
neurotoxicity
bladder toxicity
|
|
gptkbp:withdrawn
|
2013
|
|
gptkbp:bfsParent
|
gptkb:SGI_Octane
|
|
gptkbp:bfsLayer
|
6
|